SciClone Pharmaceuticals, Inc. ("SciClone") is a US-based, China-focused specialty pharmaceutical company with therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.

According to the Complaint, on June 8, 2017, SciClone announced that they had entered into a definitive agreement with affiliates of the Buyer Consortium on June 7, 2017, under which Silver Biotech Investment Limited, an affiliate of the Buyer Consortium, through its wholly-owned subsidiary, Silver Delaware Investment Limited, will acquire all of the outstanding shares of SciClone in an all-cash transaction (the “Proposed Transaction”).

The Complaint alleges that on August 2, 2017, Defendants issued materially incomplete and misleading disclosures in the Form PREM14A Preliminary Proxy Statement filed with the SEC in connection with the Proposed Transaction.

This case was voluntarily dismissed on November 20, 2017.